News

The historic approval of Ocrevus (ocrelizumab), the first-ever treatment for primary progressive multiple sclerosis (MS), set off ripples in the relatively calm waters of MS news reporting. The drug, which was also approved Tuesday as an unusually effective and safe treatment for relapsing MS, is viewed as a game-changer…

Mothers with chronic inflammatory and autoimmune diseases, such as multiple sclerosis, have a higher risk of having children with attention-deficit/hyperactivity disorder (ADHD), according to a Norwegian study. The findings were reported in a study titled “Attention-Deficit/Hyperactivity Disorder in Offspring of Mothers With Inflammatory and Immune System Diseases”…

At long last, and for the first time in medical history, people with both relapsing and primary progressive forms of multiple sclerosis have reason to celebrate. The U.S. Food and Drug Administration (FDA) today approved Ocrevus (ocrelizumab)  as a disease-modifying therapy for both forms of MS, a chronic autoimmune disease.

CGEN-15001, which could become the first tolerance-inducing therapy for multiple sclerosis (MS) and other autoimmune conditions, is on the agenda of a scientific conference in Canada that is going on now and another conference in May. The first CGEN-15001 presentation that Compugen is delivering is at the Keystone Symposia: Immune Regulation in Autoimmunity and…

Twenty years ago, the idea that B-cell depletion could treat multiple sclerosis would have been greeted with a hearty laugh by any well-respected neurologist or MS researcher — or perhaps a scoff. But times change and research advances. Today, a medicine that gets rid of certain B-cells may be the most powerful drug yet developed against…

High levels of a protein called Rab32 may contribute to the progression of multiple sclerosis (MS), leading to neuronal loss, a new study concludes. The study, “Rab32 connects ER stress to mitochondrial defects in multiple sclerosis,” appeared in the Journal of Neuroinflammation. The endoplasmic reticulum (ER) is involved in the production…

A person unlucky enough to have two specific gene variants is at significantly higher risk of developing multiple sclerosis (MS), according to a study. The research, which gave scientists insight into the processes that cause MS, also suggested that another mutation increased the effects of a known MS risk gene. The…

People with multiple sclerosis (MS) are more likely to develop kidney or bladder stones than those without MS, a new study concludes. The report, “Multiple sclerosis and nephrolithiasis: a matched-case comparative study,” appeared in the journal BJU International. Stone disease is highly lethal in patients with spinal cord injury (SCI), a condition that,…

Carol Hardaway was diagnosed with multiple sclerosis (MS) in 1990. After years of enduring relapses that brought episodes of complete blindness, numbness, tingling, debilitating fatigue, and short-term memory loss, the longtime resident of Texas — a state which offers Medicaid only to specific categories like low-income families, pregnant women, and…

Four newly published articles, the focused work of a group of researchers, evaluate the validity of four outcome measures commonly used in clinical trials of multiple sclerosis (MS) to set standards for such measures, the National MS Society recently reported. The effort by the Society-sponsored MS Outcome Assessments Consortium…

An extension of a Phase 3 clinical trial has shown that early treatment with Rebif (interferon beta-1a) in patients with initial manifestations of multiple sclerosis (MS) can prolong the time to a clinically definite multiple sclerosis (CDMS) diagnosis over five years. The study, “Subcutaneous interferon β-1a in…

The 2017 version of MuckFest MS, the five-kilometer fundraising mud-run series, will begin in a few weeks. The event, organized by the National Multiple Sclerosis Society and Event 360, features more than 18 obstacles in muddy settings. They include the swing set, muck off, skid mark, and more. Participants…

Worldwide Clinical Trials has added two webinars to its free webinar series — the first to observe Multiple Sclerosis Awareness Month in March and the second for Parkinson’s Awareness Month in April. Although both are free, attendees need to sign up in advance (see the link below). The first informative session will take place…

Swallowing difficulties and reduced cough are a major, yet commonly overlooked, issue in patients with multiple sclerosis and other brain conditions, according to Dr. Don Bolser, a University of Florida (UF) professor. Pharmaceutical companies haven’t recognized the importance of preventing bits of food and drink from getting into the lungs while…

The United States has granted a patent to Kadimastem’s stem cell-based technology for treating multiple sclerosis (MS) and other diseases of the nervous system. The patent involves the technology the company used to produce supporting cells in the central nervous system derived from human stem cells, including myelin-producing cells. The United…

Half of the more than 7,500 multiple sclerosis (MS) patients responding to a recent survey revealed they’d consider physician-assisted suicide if they could no longer enjoy anything that made life worth living. In addition, 65 percent of respondents said they’d definitely or probably let a physician terminate their lives if they were…

Alkermes has started a Phase 3 clinical trial evaluating ALKS 8700, the oral monomethyl fumarate (MMF) prodrug it is developing for the treatment of relapsing forms of multiple sclerosis (MS). The multicenter, double-blind, active-controlled trial (NCT02634307) will examine whether the gastrointestinal tract can tolerate ALKS 8700 better than Tecfidera…

Scientists have identified a receptor that promotes the influx of damaging immune T-cells into the brain of a mouse model of human multiple sclerosis (MS). The study, “EBI2 is highly expressed in multiple sclerosis lesions and promotes early CNS migration of encephalitogenic CD4 T cells,” appeared in the…

The United Kingdom’s National Institute for Health and Care Excellence (NICE) has cleared its initial doubts and now recommends Zinbryta (daclizumab) to treat relapsing multiple sclerosis (MS) in England and Wales. NICE had initially rejected Zinbryta after a first stage of the drug’s review process, due to some issues linked to…

The potential approval of Ocrevus (ocrelizumab) this month supports the idea that, someday, a world free of multiple sclerosis (MS) is possible, according to Dr. Tim Coetzee, the National Multiple Sclerosis Society’s chief advocacy, services and research officer. While Coetzee — and the society he represents — realize the potential of…

Here is a transcript of Multiple Sclerosis News Today‘s interview with Dr. Tim Coetzee — chief advocacy, services and research officer for the National Multiple Sclerosis Society — about the importance of the U.S. Food and Drug Administration (FDA)’s awaited decision on Ocrevus (ocrelizumab), and the other ongoing research. Tim…

Regulatory T-cells in the central nervous system trigger the maturation of stem cells that increase the production of myelin at injured neurons — a discovery that places the idea of regeneration in multiple sclerosis (MS) in a whole new light. Myelin is a substance essential to the functioning of the…

In recognition of multiple sclerosis (MS) awareness month, Acorda Therapeutics has launched its Alexa skill, called MS Awareness Facts.  The interactive voice-controlled service allows users to ask Amazon Alexa for information regarding MS and its debilitating symptoms. Amazon Alexa is a cloud-based service that enable customers to interact in…

Telemedicine, which allows healthcare professionals to evaluate, diagnose and treat patients at a distance with telecommunications technology, may soon benefit people with multiple sclerosis (MS). Elizabeth Morrison-Banks, MD, a health sciences clinical professor at the University of California at Riverside School of Medicine, is planning a pilot one-year study of a home-based…

MS Views and News, a non-profit multiple sclerosis (MS) advocacy organization, will host its second annual Champions Tackling MS Gala on April 22, with money raised going to support live educational events, community resources, and services intended to help improve the quality of life for people with MS. The Saturday event at the…

A clinical test of whether bionic robotics can improve mobility in people with relapsing or progressive forms of multiple sclerosis (MS) and considerable disability is now recruiting participants, after being approved by the U.K. National Health Service’s Health Research Authority (HRA) ethics committee. The trial, called RAPPER 3 (Robot Assisted Physiotherapy Exercises with Rex…

The idea of repairing damaged axons — a key component of advancing disability in multiple sclerosis (MS) — just got closer to reality, with the discovery that a compound found in fungi triggered axon regeneration, making damaged axons grow “like weeds.” Scientists have long struggled to find compounds that stimulate the…

A new test can show how exercise is benefiting people with multiple sclerosis (MS) and other neurological conditions. The evaluation of muscle health in individuals with MS, spinal cord injuries and other severe nerve damage conditions is usually done with magnetic resonance imaging (MRI) and other expensive equipment. Researchers in the…

Kinesiology professor Richard van Emmerik and his colleagues at the University of Massachusetts Amherst recently received a two-year $833,000 grant from the U.S. Department of Defense to create an improved diagnostic test for multiple sclerosis (MS). The scientists expects their research to help an estimated 2.3 million people worldwide who live with…

Researchers managed to retrain the immune system to ignore antigens that trigger an autoimmune reaction. This approach alleviated the symptoms of multiple sclerosis (MS) and type 1 diabetes in a mouse model.